Study guide
Multiphase Liver, Pancreas & Renal CT Protocols
NMTCB CT
Track your progress as you read
Finished sections get a check mark.
1 CT System Hardware & X-Ray Generation
X-Ray Tube Design and Focal Spots Tube Heat Loading, Bearings and Cooling Beam Filtration and Collimation Scanner Generations and Source/Detector Geometry Detector Technology & Data Acquisition Systems (DAS)
2 Gantry Mechanics & Ancillary Systems
Gantry Architecture, Clearance and Centering Slip Rings, Couch Motion and Load Safety Power Injector Hardware and Safety DICOM, Worklists and Image Archiving
3 Data Acquisition & Scanning Geometries
Axial vs. Helical Scanning & Pitch Mechanics Localizer/Scout Scans & Isocenter Alignment Beam Geometry, Slice Collimation & Data Sampling
4 Mathematical Reconstruction & Image Processing
Projection Data, Image Matrices and Voxel Sampling Filtered Back Projection and Reconstruction Kernels Iterative Reconstruction & AI-Powered Algorithms Hounsfield Unit Scale, Linear Attenuation & Windowing (WW/WL)
5 3D Visualization & Advanced Post-Processing
Multiplanar Reformation (MPR) & Curved Planar Reformation (CPR) Volume Rendering, Maximum/Minimum Intensity Projections & Virtual Endoscopy
6 Image Quality & Performance Metrics
Spatial Resolution, Modulation Transfer Function & Matrix Parameters MTF and Spatial-Resolution Testing Contrast Resolution, Quantum Noise & Temporal Resolution Interdependence of Image Quality Parameters & Radiation Dose
7 CT Artifacts Identification & Correction
Physics-Based Artifacts: Beam Hardening, Cupping & Partial Volume Averaging Equipment & Patient Artifacts: Ring, Motion, Metal & Windmill Effects
8 Quality Assurance & Routine Testing
Daily Quality Control: Water Calibration, Noise & Field Uniformity Periodic Quality Assurance: ACR Phantom Testing & Geometry Verification
9 Patient Communication, Screening & Preparation
Patient Identification, Clinical Screening & Pregnancy Protocols Informed Consent, Pre-Scan Fasting & Anxiety Management Patient Monitoring, Vital Signs Assessment & ECG Gating Setup
10 Infection Control & Medical Emergency Response
Infection Control, Aseptic Technique & Scanner Disinfection Medical Emergencies in the CT Suite: Vasovagal Reactions, Seizures & Code Protocols
11 Contrast Media Chemistry & Administration
Iodinated Contrast Properties: Osmolality, Viscosity & Molecular Structure Contrast Volume, Flow, Duration and Iodine Delivery Intravenous Access, Catheter Gauges & Power Injection Protocols Bolus Tracking, Test Bolus & Contrast Transit Dynamics
12 Non-Vascular Contrast & Adverse Reactions
Oral, Rectal and Enteral Contrast Intrathecal, Intra-articular and Cavitary Contrast Renal Impairment, CI-AKI Risk & Metformin Management Contrast Reactions: Categorization, Prophylaxis & Emergency Treatment
13 Neuroimaging & Head/Neck CT Protocols
Routine Brain and Trauma CT Technique Stroke, Hemorrhage and Targeted Skull-Base CT Facial Bones, Orbits & High-Resolution Temporal Bones Soft Tissue Neck & Paranasal Sinuses Protocols
14 Thoracic & Cardiovascular CT Protocols
Routine Chest CT: Pulmonary Parenchyma & Mediastinal Anatomy High-Resolution CT (HRCT) for Diffuse Interstitial Lung Disease Pulmonary Embolism & Cardiac CT Protocols
15 Abdominal & Pelvic CT Protocols
Multiphase Liver, Pancreas & Renal CT Protocols Gastrointestinal CT: Enterography, Colonography & Acute Abdomen Pelvic Cross-Sectional Anatomy & Gynecologic/Urologic Pathology
16 Musculoskeletal, Vascular & Interventional CT
Cervical, Thoracic and Lumbosacral Spine CT Extremity, Joint and Orthopedic Hardware CT CT Angiography (CTA): Carotid, Aortic & Peripheral Runoff Protocols CT-Guided Interventions: Biopsy, Abscess Drainage & Procedural Safety
17 Hybrid PET/CT and SPECT/CT Procedures
PET/CT Anatomy, Physiology and Attenuation Correction SPECT/CT Anatomy, Physiology and Attenuation Correction
18 Radiation Biology & Dose Descriptors
Radiation Physics, Cellular Interactions & Biological Risk Models Tissue Reactions, Stochastic Risk and Justification CTDI Measurement and Phantom References CTDI Weighting, Pitch and DLP Calculations Size-Specific Dose Estimates Effective-Dose Estimates and Diagnostic Reference Levels
19 Radiation Protection & Dose Optimization
Technical Dose Reduction: Tube Current Modulation & Pediatric ALARA Pediatric, Body-Habitus and Pregnancy Optimization Personnel Protection, Distance and Shielding Jurisdiction, Dose Limits and Personnel Monitoring
Multiphase Liver, Pancreas & Renal CT Protocols
Key Takeaways Explain This Topic AI
Abdominal phases follow the target organ and clinical question.
Renal enhancement alone does not establish malignancy.
Additional phases add dose and should have a specific purpose.
Last updated: October 2026
Acquisition settings and contrast timings below are illustrative adult protocol examples. Select the authorized protocol for the indication, scanner, body size, access device, and clinical condition. Treatment decisions belong to the responsible clinical team.
Hemodynamic Principles of Abdominal Multiphase CT
Computed tomography of the abdomen and pelvis requires precise synchronization between intravenous contrast media administration and image acquisition. Routine single-phase abdominal CT, commonly acquired in the portal venous phase, often answers a general question. Dedicated phases may be needed for characterizing hypervascular neoplasms, occult parenchymal lesions, vascular encasement, or collecting system pathologies. Multiphase CT exploits the distinct microvascular hemodynamics and differential perfusion rates of abdominal parenchymal organs, tumors, and vascular networks. Technologists preparing for the NMTCB(CT) specialty examination must master the physiological rationale, timing windows, contrast kinetics, and diagnostic interpretation criteria governing multiphase hepatic, pancreatic, and renal examinations.
The Dual Blood Supply & Hemodynamics of the Liver
The liver is unique among visceral organs due to its dual vascular inflow:
Portal Vein ( 75 % to 80 % 75\%\text{ to }80\% 75% to 80% of Total Hepatic Inflow): Transports deoxygenated, nutrient-rich blood from the gastrointestinal tract, spleen, and pancreas to the hepatic sinusoids at a relatively low pressure (approx. 7 to 10 mmHg 7\text{ to }10\text{ mmHg} 7 to 10 mmHg ). The portal venous transit is delayed because contrast must first traverse systemic arteries, the splanchnic capillary beds, and mesenteric veins before entering the liver.
Hepatic Artery ( 20 % to 25 % 20\%\text{ to }25\% 20% to 25% of Total Hepatic Inflow): Delivers oxygen-saturated arterial blood directly from the celiac axis via the common and proper hepatic arteries at systemic systolic pressures.
Renal enhancement is assessed by comparing consistent unenhanced and enhanced measurements while considering phase, lesion size, noise and pseudoenhancement. Measurable enhancement warrants characterization; it does not independently establish malignancy. Liver and pancreatic phases should be timed for the prescribed task and patient circulation rather than inferred from a universal percentage of tumor blood supply.
Conversely, normal hepatic parenchyma receives the vast majority of its contrast-laden blood via the portal vein. Consequently, when contrast is injected intravenously:
During the arterial phase , the arterial-fed tumor enhances intensely while the surrounding parenchyma has relatively less enhancement.
During the portal venous phase , the normal liver parenchyma reaches maximal contrast enhancement as portal blood enters the sinusoids. Meanwhile, contrast rapidly clears from the tumor's dysplastic arteriovenous channels, making the tumor appear conspicuously hypoattenuating ("washout appearance").
In contrast, hypovascular metastases (e.g., colon adenocarcinoma, breast, lung, and gastric carcinomas) receive minimal arterial supply. They appear most conspicuous as dark, non-enhancing filling defects against the brightly enhancing normal liver during the portal venous phase.
Multiphase Liver Protocol Timing & Findings
A dedicated liver protocol consists of three or four sequential helical acquisitions through the liver:
1. Pre-Contrast (Unenhanced) Phase
Technical Objectives: Scan through the entire liver prior to contrast injection. Slice thickness is typically 2.5 to 5.0 mm 2.5\text{ to }5.0\text{ mm} 2.5 to 5.0 mm .
Baseline Attenuation: Normal, unenhanced liver parenchyma demonstrates homogeneous soft-tissue attenuation ranging between + 50 and + 65 HU +50\text{ and }+65\text{ HU} + 50 and + 65 HU , which is typically 8 to 10 HU 8\text{ to }10\text{ HU} 8 to 10 HU higher than the normal unenhanced spleen ( + 40 to + 55 HU +40\text{ to }+55\text{ HU} + 40 to + 55 HU ).
Diagnostic Assessment of Hepatic Steatosis (Fatty Liver): Because lipid has negative attenuation (approx. − 100 to − 50 HU -100\text{ to }-50\text{ HU} − 100 to − 50 HU ), intracellular triglyceride accumulation reduces parenchymal attenuation. Objective CT criteria for hepatic steatosis on unenhanced scans include:
Absolute hepatic parenchymal attenuation of < 40 HU <40\text{ HU} < 40 HU ; OR
Hepatic attenuation that is > 10 HU >10\text{ HU} > 10 HU lower than splenic attenuation (spleen minus liver > 10 HU >10\text{ HU} > 10 HU ).
Additional Utility: Identifies hyperdense acute hemorrhage, baseline calcifications (granulomas, echinococcal cysts, mucinous metastases), radiopaque gallstones, and provides the baseline H U HU H U necessary to calculate true contrast enhancement ( Δ HU \Delta\text{HU} Δ HU ). Unenhanced scans also distinguish radiopaque arterial embolization beads from active tumor recurrence in treated HCC patients.
2. Late Arterial Phase ( 35 – 40 s 35\text{--}40\text{ s} 35 – 40 s Delay)
Timing Differentiation: An "early arterial phase" ( 15 – 25 seconds 15\text{--}25\text{ seconds} 15 – 25 seconds ) shows dense contrast in the celiac axis and hepatic arteries without parenchymal capillary filling (useful only for hepatic arterial CT angiography or surgical roadmapping). The late arterial phase (also known as the hepatic arterial phase , acquired at 35 – 40 seconds 35\text{--}40\text{ seconds} 35 – 40 seconds post-injection or 15 – 20 seconds 15\text{--}20\text{ seconds} 15 – 20 seconds after bolus tracking triggers at 100 HU 100\text{ HU} 100 HU in the abdominal aorta) captures peak capillary perfusion of hypervascular lesions.
Pathological Findings:
Arterial Phase Hyperenhancement (APHE): Hallmark LI-RADS feature of HCC. The lesion enhances intensely, appearing significantly brighter than the adjacent background liver.
Focal Nodular Hyperplasia (FNH): Intense, homogeneous arterial enhancement with a non-enhancing central fibrous scar.
Hepatic Adenoma: Robust, early arterial enhancement, frequently homogeneous or with areas of internal hemorrhage.
Cavernous Hemangioma: Peripheral, nodular, discontinuous globular enhancement matching aortic blood pool attenuation.
3. Portal Venous Phase ( 65 – 75 s 65\text{--}75\text{ s} 65 – 75 s Delay)
Timing & Enhancement: Acquired at 65 to 75 seconds 65\text{ to }75\text{ seconds} 65 to 75 seconds post-injection (or 40 to 50 seconds 40\text{ to }50\text{ seconds} 40 to 50 seconds post-trigger). At this stage, contrast has transited the splanchnic bed and floods the portal vein, resulting in peak parenchymal enhancement ( 100 to 150 HU 100\text{ to }150\text{ HU} 100 to 150 HU ).
Pathological Findings:
Hypovascular Liver Metastases: Colorectal and other adenocarcinoma metastases appear maximally conspicuous as dark, hypoattenuating lesions surrounded by brightly enhancing liver parenchyma.
HCC Washout Appearance: Contrast rapidly clears from the HCC into hepatic venous branches. As the surrounding liver parenchyma reaches peak enhancement, the tumor becomes distinctly hypoattenuating compared to background tissue.
HCC Pseudocapsule: A smooth, uniform enhancing rim develops around the lesion in the portal venous or delayed phase, reflecting a compressed fibrous capsule or surrounding sinusoids.
Portal Vein Thrombosis: Differentiates bland (non-enhancing) thrombus from malignant tumor thrombus (enhancing vascular invasion with APHE, expanding the vein caliber).
4. Equilibrium / Delayed Phase ( 3 – 5 min 3\text{--}5\text{ min} 3 – 5 min Delay)
Timing & Hemodynamics: Scanned at 180 to 300 seconds 180\text{ to }300\text{ seconds} 180 to 300 seconds post-injection. Systemic arterial and venous contrast concentrations achieve equilibrium, and contrast redistributes into the extracellular interstitial space.
Pathological Findings:
Definitive HCC Washout & Capsule: Confirms true washout appearance (a major LI-RADS criterion) and delineates the enhancing pseudocapsule against faded parenchyma.
Cavernous Hemangioma Centripetal Fill-In: Peripheral globular puddling seen on arterial phases progresses inward (centripetally), resulting in complete or partial uniform fill-in that remains iso-attenuating or hyperattenuating to the blood pool on delayed images.
Intrahepatic Cholangiocarcinoma (ICC): Peripheral, irregular arterial enhancement followed by progressive, prolonged delayed enhancement on 3- to 5-minute scans, caused by contrast retention within the dense, desmoplastic fibrous stroma characteristic of bile duct tumors.
Multiphase Pancreatic CT Protocol
Pancreatic adenocarcinoma carries a dismal prognosis, and computed tomography is the gold standard imaging modality for determining surgical resectability. Resectability hinges on defining tumor relationship to adjacent vascular structures: the celiac axis, common hepatic artery (CHA), superior mesenteric artery (SMA), superior mesenteric vein (SMV), and portal vein (PV).
Protocol Parameters
Oral Contrast: Neutral contrast (plain water or negative enteral contrast, 500 – 750 mL 500\text{--}750\text{ mL} 500 – 750 mL ingested immediately before scanning). Water distends the stomach and duodenal C-loop without causing beam hardening artifacts that would obscure the pancreatic head, ampulla, or peripancreatic arterial calcifications.
Intravenous Contrast Delivery: High delivery rate of 4.0 to 5.0 mL/s 4.0\text{ to }5.0\text{ mL/s} 4.0 to 5.0 mL/s via an 18- or 20-gauge antecubital peripheral catheter. Standard volume is 100 to 150 mL 100\text{ to }150\text{ mL} 100 to 150 mL of high-concentration iodinated contrast ( 350 to 370 mg I/mL 350\text{ to }370\text{ mg I/mL} 350 to 370 mg I/mL ).
Assess enhancement, lesion margins, ducts and vascular relationships together. Arterial enhancement and washout can support hepatocellular carcinoma in the appropriate at-risk population using the applicable diagnostic system; they are not universally diagnostic in every patient. Pancreatic tumor contact with arteries and veins must be described for multidisciplinary assessment, because one contact-angle cutoff alone does not establish resectability for all vessels and circumstances.
1. Pancreatic parenchymal phase
A dedicated pancreatic phase, often around 35–50 seconds in an illustrative adult protocol, emphasizes pancreatic enhancement and relevant arterial anatomy. Thin multiplanar images show the pancreatic head within the duodenal C-loop, the body anterior to the splenic vein and the tail toward the splenic hilum. Compare a lesion with background pancreas, look for ductal dilation and describe vessel contact. A venous phase complements this by assessing veins and the metastatic survey. Timing and selected phases follow the supervising protocol.
2. Portal Venous Phase ( 65 – 70 s 65\text{--}70\text{ s} 65 – 70 s Delay)
Diagnostic Objective: Maximally opacifies the mesenteric-portal venous axis: the superior mesenteric vein, splenic vein, and portal vein confluence.
Venous Invasion Criteria: Assesses tumor impingement, caliber narrowing, venous contour irregularity, intraluminal tumor thrombus, or occlusion of the SMV and PV. Evaluates whether venous reconstruction is surgically feasible.
Metastatic Survey: Complete coverage of the liver and peritoneum to detect occult hepatic metastases or peritoneal carcinomatosis.
Multiphase Renal CT Protocol & Bosniak Classification
Multiphase renal CT is indicated for evaluating gross or microscopic hematuria, staging known renal cell carcinoma (RCC), characterizing indeterminate cystic or solid masses, and conducting CT urography.
2. Corticomedullary Phase ( 30 – 40 s 30\text{--}40\text{ s} 30 – 40 s Delay)
Hemodynamics: High-rate arterial inflow selectively opacifies the renal cortex and columns of Bertin ( > 150 HU >150\text{ HU} > 150 HU ), while the tubular fluid has not yet reached the renal medullary pyramids, leaving the medulla unenhanced and dark.
Diagnostic Role: Delineates renal arterial anatomy (accessory or aberrant renal arteries for pre-surgical partial nephrectomy planning) and identifies renal arteriovenous malformations.
Renal Vein Thrombosis: Optimal phase for detecting tumor thrombus extending from an RCC into the main renal vein or inferior vena cava (IVC).
Limitation: Inadequate for characterizing renal masses located within or abutting the renal medulla, as unenhanced pyramids mimic hypoenhancing tumors.
3. Nephrographic Phase ( 80 – 100 s 80\text{--}100\text{ s} 80 – 100 s Delay)
Hemodynamics: Contrast is filtered across glomeruli into the loops of Henle and collecting tubules, producing uniform, homogeneous parenchymal enhancement across both the cortex and medulla ( 100 to 120 HU 100\text{ to }120\text{ HU} 100 to 120 HU ).
The Gold Standard Phase: This is the single most sensitive phase for detecting, delineating, and characterizing renal parenchymal neoplasms. Normal renal tissue enhances homogeneously, maximizing contrast against RCCs.
Enhancement measurement: compare matched unenhanced and enhanced ROIs. An increase around 20 HU supports measurable enhancement; less than 10 HU generally supports nonenhancement, with intermediate change requiring assessment. Noise, partial volume and pseudoenhancement complicate small-lesion measurements. Enhancement does not prove cancer or automatically require surgery.
4. Excretory / Pyelographic Phase ( 5 – 15 min 5\text{--}15\text{ min} 5 – 15 min Delay)
Hemodynamics: Contrast is concentrated and excreted into the calyces, renal pelvis, ureters, and urinary bladder.
Diagnostic Role: Evaluates the urothelium in CT Urography (CTU). Detects filling defects caused by urothelial carcinoma (transitional cell carcinoma), fibroepithelial polyps, ureteral strictures, and papillary necrosis.
Cystic renal masses: Bosniak version 2019
Apply the Bosniak system to an appropriately characterized cystic renal mass, not to every enhancing solid mass. Version 2019 uses morphology and enhancement: a thin wall or septum is at most 2 mm, minimal thickening is 3 mm, and thickening of at least 4 mm or irregular enhancing wall/septa supports category III. Category IIF includes specified minimally thickened or many thin enhancing septa. Enhancing nodules support category IV, with the defined angle and size criteria. The old 3 cm cutoff for an otherwise homogeneous hyperattenuating nonenhancing cyst is not retained as an automatic IIF rule.
An enhancement difference around 20 HU can support measurable CT enhancement when properly measured, but small lesions can show pseudoenhancement and noisy measurements. Enhancement does not by itself prove renal cell carcinoma. Compare unenhanced and enhanced data using consistent ROIs and appropriate phase selection. Categories guide risk assessment; management depends on patient factors and the treating team rather than an automatic surgical instruction in a technical guide.
Renal, adrenal and urinary questions
A noncontrast stone examination depicts calculi in the kidneys and ureters and their secondary obstruction signs without needing an IV bolus. Trace the ureter from the renal pelvis to the bladder and distinguish a ureteric calculus from adjacent vascular calcification or a phlebolith. CT urography adds appropriately selected phases to evaluate renal tissue and the collecting system; an excretory phase emphasizes ureters and urothelial lesions rather than serving as a substitute for retrograde traumatic cystography.
Adrenal CT may characterize a lesion using unenhanced attenuation and, when specifically ordered, delayed enhancement behavior. Washout calculations require the correct acquisitions and cannot classify every lesion in isolation. An adrenal mass should not be biopsied without the clinical team addressing the possibility of pheochromocytoma. Multiphase imaging carries added dose, so use the phases needed for the actual question.
Reference: Bosniak version 2019 proposal .
Routine abdominal assessment and trauma
Routine abdominal CT commonly covers the diaphragmatic domes through the prescribed pelvic endpoint, using a phase chosen for the question. Follow the liver and spleen, pancreas, kidneys, adrenals, bowel, mesentery, aorta and retroperitoneum through consecutive slices. Coronal and sagittal reformations help relate a lesion to organ boundaries and vessels. Do not add every multiphase protocol to a routine examination.
In trauma, maintain resuscitation and immobilization and follow the ordered range and phase plan. Contrast-enhanced data can show organ laceration, devascularization, hematoma and active bleeding. Arterial or delayed phases may be selected for a vascular or urinary-leak question, with added dose weighed against the clinical need. Compare a focus across phases to help distinguish contained vascular injury from spreading extravasation. A noncontrast scan cannot exclude active bleeding merely because no dense focus is visible.
The spleen lies beneath the left diaphragm beside the stomach and left kidney; renal and splenic injuries can share nearby fluid. Trace organ margins and collecting systems rather than attributing all left upper abdominal fluid to one source. For adrenal assessment, identify the right gland near the IVC and the left gland anterior-medial to the kidney. Unenhanced attenuation and selected washout measurements can help characterize a mass, but neither establishes every histologic diagnosis.